We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Icosapent Ethyl (Vascepa / Vazkepa) — purified EPA ethyl ester
A prescription, highly-purified ethyl ester of EPA (Vascepa) — NOT a fish-oil supplement. At 4 g/day it lowers triglycerides and, in the REDUCE-IT trial of statin-treated high-risk patients, cut major cardiovascular events ~25%. Honest caveats: the mechanism of benefit is debated (the trial's mineral-oil comparator may have inflated the effect), it modestly raises atrial fibrillation and bleeding risk, and OTC omega-3/fish-oil supplements did NOT show the same benefit. Prescription drug, not a supplement.
Prescription medication — not a dietary supplement
Icosapent Ethyl (Vascepa) is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Icosapent Ethyl (Vascepa) doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2011–2026 with a typical study size of 13,078 participants.
Based on 88 studies · 1 meta-analysis · 42 RCTs · 13,078 total participants
Confidence
High confidenceBy outcome
Icosapent ethyl has one large, well-powered outcome trial (REDUCE-IT) showing a ~25% reduction in major cardiovascular events in statin-treated high-triglyceride patients, plus consistent triglyceride-lowering RCTs (MARINE, ANCHOR). But the mechanism of the cardiovascular benefit is debated, the mineral-oil comparator may have inflated the effect, a contrasting omega-3 trial (STRENGTH) showed no benefit, and the drug modestly raises atrial fibrillation and bleeding risk — so the evidence is strong but not unambiguous, and it does NOT generalize to OTC fish oil.
46 randomised trials
89% were about Icosapent Ethyl (Vascepa) in an audit of 46 of them
Every randomised or controlled trial of Icosapent Ethyl (Vascepa) indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
8 trials ongoing or recruiting · 33 completed on ClinicalTrials.gov
14 of the completed trials have posted results
Registered trials show research momentum for Icosapent Ethyl (Vascepa), not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Icosapent ethyl (Vascepa in the US, Vazkepa in the EU; trial name AMR101) is a prescription omega-3 — a highly purified ethyl ester of eicosapentaenoic acid (EPA) only, containing no DHA. This is the crucial distinction from OTC fish-oil capsules, which are mixed EPA/DHA at far lower doses.
Taken at 4 g/day with food, it lowers triglycerides (~20–35% in hypertriglyceridemic patients in the MARINE and ANCHOR trials) and has pleiotropic effects beyond lipid-lowering: membrane stabilization, anti-inflammatory and antioxidant activity, and improved endothelial function.
Its landmark evidence is REDUCE-IT (Bhatt 2019, NEJM), a randomized trial of ~8,200 statin-treated patients with elevated triglycerides and high cardiovascular risk, which showed a significant ~25% relative reduction in major adverse cardiovascular events (cardiovascular death, MI, stroke, revascularization, unstable angina).
That is a genuinely large, prospective outcome benefit — rare for a lipid-adjacent therapy.
The honest complications: (1) the magnitude of benefit exceeds what triglyceride-lowering alone explains, so the true mechanism is debated; (2) the comparator in REDUCE-IT was mineral oil, which mildly raised LDL/CRP in the placebo arm and may have inflated the apparent benefit; (3) a separate large trial of a mixed EPA/DHA omega-3 (STRENGTH, Nicholls 2020, JAMA) against a corn-oil placebo found NO cardiovascular benefit, as did several fish-oil supplement trials (e.g.
VITAL) — so the benefit is specific to high-dose purified EPA, not omega-3 supplements generally; and (4) icosapent ethyl modestly increases the risk of atrial fibrillation and of serious bleeding.
The score reflects one strong, well-powered outcome trial and consistent triglyceride-lowering data, tempered by the unresolved mechanism/comparator debate and real arrhythmia and bleeding trade-offs.
This is a prescription drug for a defined clinical population — it is not a substitute for, nor equivalent to, an over-the-counter fish-oil supplement.
EPA reduces hepatic VLDL-triglyceride production and enhances clearance, lowering plasma triglycerides ~20–35% at 4 g/day — most in patients with high baseline levels.
EPA incorporates into cell membranes, providing antioxidant, membrane-stabilizing, anti-inflammatory, and endothelial effects proposed to explain cardiovascular benefit beyond lipid-lowering.
EPA is a substrate for specialized pro-resolving mediators and lowers inflammatory signaling, contributing to plaque stabilization in the proposed (but debated) mechanism.
How Icosapent Ethyl (Vascepa) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Use with caution — the AF signal is concentrated in those with a prior history; monitor rhythm.
Monitor for bleeding; the combination raises bleeding risk, especially perioperatively.
Not a self-directed swap — it is a prescription drug for a defined high-risk population, and OTC fish oil did not show the same benefit.
Additive bleeding risk; icosapent ethyl can prolong bleeding time.
Icosapent ethyl modestly increases atrial fibrillation risk; monitor in patients with prior AF.
Tip: Higher in patients with prior AF; monitor for palpitations and report them. Seen consistently in REDUCE-IT and real-world data.
Tip: Risk is amplified by concurrent antithrombotics; watch for unusual bruising/bleeding, especially around procedures.
Tip: Generally mild and tolerable; taking with food can reduce GI complaints.
Icosapent Ethyl (Vascepa) has an evidence score of 4.2/10 — emerging evidence based on 88 indexed studies, including 1 meta-analysis. A prescription, highly-purified ethyl ester of EPA (Vascepa) — NOT a fish-oil supplement. At 4 g/day it lowers triglycerides and, in the REDUCE-IT trial of statin-treated high-risk patients, cut major cardiovascular events ~25%. Honest caveats: the mechanism of benefit is debated (the trial's mineral-oil comparator may have inflated the effect), it modestly raises atrial fibrillation and bleeding risk, and OTC omega-3/fish-oil supplements did NOT show the same benefit. Prescription drug, not a supplement. Representative study: PMID 35290840.
Dosing for Icosapent Ethyl (Vascepa): Approved dose is 2 g twice daily (4 g/day total) taken with food, under a clinician, for statin-treated adults with elevated triglycerides and high cardiovascular risk. A prescription drug — not a self-directed regimen. Individual needs vary, so check the right dose for you with a healthcare provider.
The best time to take Icosapent Ethyl (Vascepa) is with meals. Take it with food. Taken with food to maximize absorption of the lipophilic ethyl ester; split as 2 g twice daily.
Icosapent Ethyl (Vascepa) should be used with caution — talk to a healthcare provider before taking it. Reported side effects include new-onset atrial fibrillation / flutter, bleeding (including serious bleeding), musculoskeletal pain / peripheral edema / constipation. How often they occur is not established for all of them. Use caution if any of these apply to you: Known hypersensitivity to icosapent ethyl or its components; Caution with fish/shellfish allergy (limited data); Active serious bleeding.
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism. Its only head-to-head trial with metformin cited here was a 36-person pilot, which does not show it can replace metformin.
Canakinumab
Too few graded studiesAn injectable anti-interleukin-1β monoclonal antibody (Ilaris), approved for rare periodic fever syndromes. Famous for the landmark CANTOS trial — the first proof that lowering inflammation alone (without touching lipids) cuts cardiovascular events, validating the 'inflammaging' hypothesis. But CANTOS showed NO all-cause-mortality benefit and MORE fatal infections, and the follow-up cancer trials failed. An extremely expensive prescription biologic, not a supplement.
Pioglitazone (Actos)
Too few graded studiesAn oral thiazolidinedione (Actos) diabetes drug that improves insulin sensitivity via PPAR-gamma. It drew geroscience interest after reducing recurrent stroke/MI in insulin-resistant non-diabetics (IRIS) and improving NASH liver histology — but weight gain, fluid retention / heart-failure risk, fracture risk, and a debated bladder-cancer signal keep enthusiasm in check. Prescription drug, not a supplement.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 88 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research